

Progetto **CANOA**
**CARCINOMA
MAMMARIO:**

QUALI NOVITA' PER IL 2016?

"Saper leggere" uno studio clinico per migliorare la pratica clinica

Coordinatori scientifici:
Stefania Gori
Giovanni L. Pappagallo



Ospedaletto di Pescantina (VR) 22-23 Aprile 2016
Villa Quaranta Park Hotel

QUESITO GRADE: nelle pazienti con carcinoma mammario HER-2 + metastatico senza metastasi viscerali, l'aggiunta del Pertuzumab al Trastuzumab + taxano è raccomandabile rispetto al Trastuzumab + taxano?

Discussione sulla qualità e sulla rilevanza clinica delle evidenze

Dott.ssa ELENA FIORIO AOUI Verona

Author(s):

Date:

Question: Pertuzumab compared to Trastuzumab for 1a linea MBC HER2+

Setting: malattia non viscerale

Bibliography:

Quality assessment							N ^o of patients		Effect		Quality	Importance
N ^o of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Pertuzumab	Trastuzumab	Relative (95% CI)	Absolute (95% CI)		
OS (follow up: median 50 months; assessed with: KM)												
1	randomised trials	not serious	not serious	not serious	very serious ¹	none	30/88 (34.1%)	28/90 (31.1%)	HR 1.11 (0.66 to 1.85)	3 more per 100 (from 9 fewer to 19 more) 4	⊕⊕○○ LOW	CRITICO
PFS (follow up: median 50 months; assessed with: KM)												
1	randomised trials	not serious	not serious	not serious	serious ²	none	-/88	-/90	HR 0.83 (0.58 to 1.18)	-- per 100 (from -- to --)	⊕⊕⊕○ MODERATE	CRITICO
Cardiotox (assessed with: CTC-AE)												
1	randomised trials	not serious	not serious	serious	not serious ³	none	27/408 (6.6%)	34/396 (8.6%)	RR 0.785 (0.482 to 1.278)	2 fewer per 100 (from 2 more to 4 fewer)	⊕⊕⊕○ MODERATE	CRITICO
Tox. limitante												
1	randomised trials	not serious	not serious	serious ⁴	not serious ³	none	31/397 (7.8%)	30/407 (7.4%)	RR 1.057 (0.652 to 1.716)	0 fewer per 100 (from 3 fewer to 5 more)	⊕⊕⊕○ MODERATE	CRITICO

CI: Confidence interval; **HR:** Hazard Ratio; **RR:** Risk ratio

1. LC95% compatibili con conclusioni cliniche di segno opposto (-2)
2. LC95% compatibili con conclusioni cliniche di segno opposto (-1)
3. Non downgrade per imprecisione, data la bassa incidenza dell'AE
4. No explanation was provided